ADVENTRX’s ANX-514 (Docetaxel Emulsion) Demonstrated Positive Data from Preclinical Pharmacokinetic Testing
Preclinical pharmacokinetic testing of ANX-514 (docetaxel emulsion) in a well recognized animal model, yielded positive data as recently announced by ADVENTRX Pharmaceuticals, Inc. (Amex: ANX).
Results of the study indicated the following:
- Bioequivalent pharmacokinetics between ANX-514 and the FDA-approved version of docetaxel: Taxotere®
- ANX-514 administered intravenously did not cause hypersensitivity reactions in this study, as opposed to acute hypersensivity reactions observed following intravenous treatment with Taxotere®.
ANX-514 is a novel emulsion formulation of docetaxel - an agent for the treatment of breast, non-small cell lung, prostate and gastric cancers.
According to Evan M. Levine, chief executive officer for ADVENTRX:
"These preclinical results are important and strengthen our belief that ANX-514 is an appropriate candidate for marketing approval under the shorter timelines available under Section 505(b)(2).
In addition, these results suggest that treatment with ANX-514 may eliminate the need for multi-day premedication with corticosteroids prior to treatment, which is currently recommended prior to treatment with Taxotere."Find more details from the full report.
Comment Preview